BRIEF—Ipsen and MD Anderson agree deal on promising cancer candidate

French pharma firm Ipsen and The MD Anderson Cancer Center in Texas, USA, have agreed terms for a global licensing and joint development deal, related to a pre-clinical oncology candidate.

MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.

The two organizations will also work together on additional preclinical studies to further explore the potential of the drug candidate’s mode-of-action and expanded indications.

Financial details were not disclosed.